NEW YORK, NY / ACCESSWIRE / October 4, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
CPNG Shareholders Click Here: https://www.zlk.com/pslra-1/coupang-class-action-submission-form?prid=32419&wire=1
HGEN Shareholders Click Here: https://www.zlk.com/pslra-1/humanigen-inc-lawsuit-submission-form?prid=32419&wire=1
SMFR Shareholders Click Here: https://www.zlk.com/pslra-1/sema4-lawsuit-loss-submission-form?prid=32419&wire=1
* ADDITIONAL INFORMATION BELOW *
Coupang, Inc. (NYSE:CPNG)
This lawsuit is on behalf of all purchasers of Coupang Class A common stock pursuant and/or traceable to the registration statement issued in connection with Coupang's March 2021 initial public offering.
Lead Plaintiff Deadline: October 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/coupang-class-action-submission-form?prid=32419&wire=1
According to the filed complaint, (a) Coupang was engaged in improper anti-competitive practices with its suppliers and other third parties in violation of applicable regulations, including: (i) pressuring suppliers to raise prices of products on competing e-commerce platforms to ensure Coupang's prices would be more competitive; (ii) coercing suppliers into purchasing advertisements that would benefit Coupang financially; (iii) forcing suppliers to shoulder all expenses from sales promotions; and (iv) requesting wholesale rebates from suppliers without specifying any terms relating to rebate programs, all of which served to artificially maintain Coupang's lower prices and artificially inflate Coupang's historical revenues and market share; (b) Coupang had improperly adjusted search algorithms and manipulated product reviews on its marketplace platform to prioritize its own private-label branded products over those of other sellers and merchants, to the detriment of consumers, merchants, and suppliers; (c) unbeknownst to its Rocket WOW members, Coupang was selling products to non-member customers at lower prices than those offered to its Rocket WOW members; (d) Coupang subjected its workforce to extreme, unsafe, and unhealthy working conditions; (e) all of the above illicit practices exposed Coupang to a heightened, but undisclosed, risk of reputational and regulatory scrutiny that would harm Coupang's critical relationships with consumers, merchants, suppliers, and the workforce; and (f) Coupang's lower prices, historical revenues, competitive advantages, and growing market share were the result of systemic, improper, unethical, and/or illegal practices, and, thus, unsustainable.
Humanigen, Inc. (NASDAQ:HGEN)
HGEN Lawsuit on behalf of: investors who purchased May 28, 2021 - July 12, 2022
Lead Plaintiff Deadline: October 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/humanigen-inc-lawsuit-submission-form?prid=32419&wire=1
According to the filed complaint, during the class period, Humanigen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Humanigen's lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab's clinical and commercial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Sema4 Holdings, Corp. (NASDAQ:SMFR)
SMFR Lawsuit on behalf of: investors who purchased March 14, 2022 - August 15, 2022
Lead Plaintiff Deadline: November 7, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sema4-lawsuit-loss-submission-form?prid=32419&wire=1
According to the filed complaint, during the class period, Sema4 Holdings, Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) there was a significant risk that Sema4 would reverse a material amount of previously recognized revenue that it could not recoup from third party payors; (2) the Company was experiencing declining selling prices for its reproductive health segment; (3) as a result of the foregoing, Sema4's financial results would be adversely affected; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: